FI3864053T3 - Rms:n hoito vaihtohoidolla - Google Patents

Rms:n hoito vaihtohoidolla Download PDF

Info

Publication number
FI3864053T3
FI3864053T3 FIEP20785440.7T FI20785440T FI3864053T3 FI 3864053 T3 FI3864053 T3 FI 3864053T3 FI 20785440 T FI20785440 T FI 20785440T FI 3864053 T3 FI3864053 T3 FI 3864053T3
Authority
FI
Finland
Prior art keywords
ofatumumab
use according
treatment
modifying treatment
disease
Prior art date
Application number
FIEP20785440.7T
Other languages
English (en)
Finnish (fi)
Inventor
Krishnan Ramanathan
Dieter Adrian Haering
Morten Bagger
Martin Merschhemke
Marina Ziehn
Ratnakar Pingili
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72709332&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI3864053(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of FI3864053T3 publication Critical patent/FI3864053T3/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FIEP20785440.7T 2019-09-11 2020-09-10 Rms:n hoito vaihtohoidolla FI3864053T3 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19196789 2019-09-11
EP20154736 2020-01-30
PCT/EP2020/075332 WO2021048280A1 (en) 2019-09-11 2020-09-10 Treatment of rms by switching therapy

Publications (1)

Publication Number Publication Date
FI3864053T3 true FI3864053T3 (fi) 2023-09-13

Family

ID=72709332

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP20785440.7T FI3864053T3 (fi) 2019-09-11 2020-09-10 Rms:n hoito vaihtohoidolla

Country Status (15)

Country Link
US (1) US20220298253A1 (enExample)
EP (2) EP4230655A3 (enExample)
JP (2) JP7794735B2 (enExample)
KR (1) KR20220062025A (enExample)
CN (3) CN114401742B (enExample)
AU (1) AU2020344154A1 (enExample)
CA (1) CA3150947A1 (enExample)
DK (1) DK3864053T3 (enExample)
ES (1) ES2957112T3 (enExample)
FI (1) FI3864053T3 (enExample)
IL (1) IL290619A (enExample)
LT (1) LT3864053T (enExample)
MX (1) MX2022003010A (enExample)
SI (1) SI3864053T1 (enExample)
WO (1) WO2021048280A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3733712T (lt) 2016-08-15 2023-09-11 Novartis Ag Išsėtinės sklerozės gydymo schemos ir būdai, panaudojant ofatumumabą
US20220389109A1 (en) * 2019-09-11 2022-12-08 Novartis Ag Management of conditions other than multiple sclerosis in ofatumumab-treated patients
EP4707302A2 (en) * 2020-04-09 2026-03-11 Novartis AG Ofatumumab for treating ms while maintaining serum igg
WO2022219057A1 (en) * 2021-04-14 2022-10-20 Novartis Ag Ofatumumab for treating multiple sclerosis in asian patients

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0315295C1 (pt) 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
AR073295A1 (es) * 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
EP2692343A1 (en) * 2012-08-03 2014-02-05 Forward Pharma A/S Combination therapy for treatment of multiple sclerosis
WO2015168103A1 (en) * 2014-04-29 2015-11-05 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
LT3733712T (lt) 2016-08-15 2023-09-11 Novartis Ag Išsėtinės sklerozės gydymo schemos ir būdai, panaudojant ofatumumabą

Also Published As

Publication number Publication date
MX2022003010A (es) 2022-06-02
CN118403156A (zh) 2024-07-30
LT3864053T (lt) 2023-09-11
JP7794735B2 (ja) 2026-01-06
ES2957112T3 (es) 2024-01-11
WO2021048280A1 (en) 2021-03-18
JP2026016387A (ja) 2026-02-03
EP3864053B1 (en) 2023-07-05
IL290619A (en) 2022-04-01
CN114401742A (zh) 2022-04-26
CN114401742B (zh) 2024-05-24
EP4230655A2 (en) 2023-08-23
KR20220062025A (ko) 2022-05-13
US20220298253A1 (en) 2022-09-22
CN118436777A (zh) 2024-08-06
EP4230655A3 (en) 2023-11-01
CA3150947A1 (en) 2021-03-18
EP3864053A1 (en) 2021-08-18
AU2020344154A1 (en) 2022-04-07
JP2022548575A (ja) 2022-11-21
SI3864053T1 (sl) 2023-12-29
DK3864053T3 (da) 2023-09-11

Similar Documents

Publication Publication Date Title
FI3864053T3 (fi) Rms:n hoito vaihtohoidolla
FI3493812T3 (fi) Imetelstaatin ja venetoklaksin yhdistelmiä akuutin myelooisen leukemian hoitoa varten
FI3634419T3 (fi) Gonadotropiinia vapauttavan hormonin antagonistin käsittävä annostusohjelma kohdun myoomien hoitamiseksi ja kuukautisten aiheuttaman verenhukan vähentämiseksi
JP2020521797A5 (enExample)
RU2013123646A (ru) Комбинированная композиция
RU2010142456A (ru) Синергические комбинации 5'-метилтиоаденозина
IL292612A (en) Treatment methods using mtorc1 modulator
MX2022012310A (es) Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton.
RU2015140572A (ru) Способы лечения колоректального рака
KR910700045A (ko) Hiv 감염 관련 질병의 치료
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
WO2005072742A1 (en) Treatment of psychoses with quetiapine antipsychotic
HRP20090679T1 (hr) Upotreba oksikodona za liječenje organske boli
JP2019507786A5 (enExample)
PT1656131E (pt) Utilização de betaína para tratar claudicação intermitente
FI3359572T3 (fi) Menetelmä multippeliskleroosin hoitamiseksi
JP2021535163A5 (enExample)
JP2003503453A5 (ja) ガバペンチンおよびプレガバリンを含む相乗作用組成物
HRP20211661T1 (hr) Igmezin, namijenjen upotrebi u liječenju alzheimerove bolesti
RU2006139819A (ru) Применение симетикона для предрасположенных к запорам пациентов
FI4255563T3 (fi) 5’-o-fenyyliasetyyliuridiini ja terapeuttinen käyttö
RU2020108631A (ru) Новая вспомогательная терапия для применения в способе лечения рака простаты
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
JP2021530568A5 (enExample)
RU2369393C2 (ru) Применение окскарбазепина для лечения диабетической нейропатической боли и для улучшения сна